Determinants of 5-Year Survival in Patients with Advanced NSCLC with PD-L1≥50% Treated with First-Line Pembrolizumab Outside of Clinical Trials: Results from the Pembro-real 5Y Global Registry
JOURNAL FOR IMMUNOTHERAPY OF CANCER(2025)
关键词
Immunotherapy,Immune Checkpoint Inhibitor,Lung Cancer
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要